Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
NCT ID: NCT04802382
Last Updated: 2022-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
252 participants
INTERVENTIONAL
2021-06-11
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The severe acute respiratory syndrome-associated coronavirus disease 2019 (COVID-19) illness results from the immediate response to the viral infection as well as from a subsequent host inflammatory response. Systemic proinflammatory cytokines and biomarkers are elevated as the disease progresses towards its advanced stages, and correlate with worse chances of survival.
Serum cytokine levels that are elevated in patients with Covid-19-associated cytokine storm include interleukin-1β, interleukin-6, IP-10, TNF, interferon-γ, macrophage inflammatory protein (MIP) 1α and 1β, and VEGF. Higher interleukin-6 levels are strongly associated with shorter survival. The relative frequencies of circulating activated CD4+ and CD8+ T cells and plasmablasts are increased in Covid-19. In addition to the elevated systemic cytokine levels and activated immune cells, several clinical and laboratory abnormalities, such as elevated CRP and d-dimer levels, hypoalbuminemia, renal dysfunction, and effusions, are also observed in Covid-19. Laboratory test results reflecting hyper inflammation and tissue damage were found to predict worsening outcomes in Covid-19.
CimetrA, comprising Artemisinin, Curcumin, Boswellia, and Vitamin C in a nanoparticular formulation, has been studied on patients with COVID-19 in a randomized double-blind control Phase II study (MGC-006 - under a previous product name - ArtemiC). The study product demonstrated excellent safety and efficacy profiles.
Experiments performed in vitro with CimetrA demonstrated the ability to reduce cytokine elevation in response to stimulation of human PBMC preparations.
The currently proposed Multi-center multinational-controlled study is designed to include 252 adult patients who suffer from moderate COVID-19 infection. Safety will be assessed through collection and analysis of adverse events, blood and urine laboratory assessments, and vital signs.
After the screening visit, the study drug will be administrated twice a day morning and evening (every 12 hours) during (day 1 and day 2) The patients will be randomized in 1:1:1 ratio to study drug (CimetrA) in addition to Standard of Care (Arm 1 (CimetrA-1) or Arm 2 (CimetrA-2)) or Placebo in addition to Standard of Care (Arm 3).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System
NCT04353245
Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients
NCT04501965
Asymptomatic COVID-19 Infection Among Healthcare Workers
NCT04354792
A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects
NCT04801017
Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients
NCT04502342
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
252 adult patients who suffer from COVID-19 infection and do not participate in any other clinical trial. The patient must not agree to participate in any new clinical study during the study duration. The study will take place during the patient's hospitalization due to a COVID-19 infection. The study will last up to 4 weeks, until the conclusion on day 28. In case of hospital discharge within the study period, follow-up will continue per protocol until day 28 wherever the subject will be located, performed via phone call or in-clinic, depending on the status of the patient and study schedule.
Day 1 Prior to engaging in any study procedures, the subject must meet the inclusion/exclusion criteria by history (which includes a signed declination), and review and sign an ICF. Following procedures will be performed during the visit -
* Inclusion/Exclusion criteria evaluation
* Informed Consent
* Medical History
* Concomitant Medications
* Physical Examination
* Vital Signs
* Hematology blood test (local, mandatory even if there are available results from the day before)
* Biochemistry blood test (local, mandatory even if there are available results from the day before)
* NEWS score
* PK test (brazil only, central)\*
* Blood test for inflammatory markers (IL-6, IL-1β, IL-12, TNF α, IFN-γ) (local)
* D-Dimer test (local)
* VAS scale
* Urine pregnancy test for women of childbearing potential
* ECG
* COVID-19-Impact on Quality of Life Questionnaire (will be completed by the staff based on the patient answer)
* Randomization in 1:1:1 ratio to study drug (CimetrA) in addition to Standard of Care (Arm 1 (CimetrA-1) or Arm 2 (CimetrA-2)) or Placebo in addition to Standard of Care (Arm 3)
* Treatment administration (twice a day, morning and evening)
* Test for detection COVID-19 (within 5 days from admission to hospital)
Day 2
* Concomitant Medications
* AE Assessment
* Physical Examination
* Vital Signs
* Hematology blood test (local, mandatory even if there are available results from the day before)
* Biochemistry blood test (local, mandatory even if there are available results from the day before)
* NEWS score
* Blood test for inflammatory markers (IL-6, IL-1β, IL-12, TNF α, IFN-γ) (local)
* D-Dimer test (local)
* VAS scale
* Treatment administration (twice a day, morning and evening)
Days 3-6
* Concomitant Medications
* AE assessment
* Physical Examination
* Vital Signs
* Hematology blood test \*\*
* Biochemistry blood test \*\*
* News score \*\*
* Blood test for inflammatory markers (IL-6, IL-1β, IL-12, TNF α, IFN-γ) (local)
* VAS scale
Day 7
* Concomitant Medications
* AE assessment
* Physical Examination
* Vital Signs
* Hematology blood test (local, mandatory even if there are available results from the day before)
* Biochemistry blood test (local, mandatory even if there are available results from the day before)
* News score
* Blood test for inflammatory markers (IL-6, IL-1β, IL-12, TNF α, IFN-γ) (local)
* D-Dimer test (local)
* VAS scale
* COVID-19-Impact on Quality of Life Questionnaire (will be completed by the staff based on the patient answer)
Days 8-13
* Concomitant Medications
* AE assessment
* Physical Examination
* Vital Signs
* Hematology blood test \*\*
* Biochemistry blood test \*\*
* News score \*\*
* VAS scale
Day 14
* Concomitant Medications
* AE assessment
* Physical Examination
* Vital Signs
* Hematology blood test (local, mandatory even if there are available results from the day before)
* Biochemistry blood test (local, mandatory even if there are available results from the day before)
* News score
* Blood test for inflammatory markers (IL-6, IL-1β, IL-12, TNF α, IFN-γ) (local)
* D-Dimer test (local)
* VAS scale
* Test for detection COVID-19
* COVID-19-Impact on Quality of Life Questionnaire (will be completed by the staff based on the patient answer)
Day 21 (phone visit)
* Concomitant Medications
* AE assessment
* VAS scale
* COVID-19-Impact on Quality of Life Questionnaire (will be completed by the staff based on the patient answer)
Day 28 - Follow Up (clinic visit)
* Concomitant Medications
* AE assessment
* Physical Examination
* Vital Signs
* Hematology blood test (local, mandatory even if there are available results from the day before)
* Biochemistry blood test (local, mandatory even if there are available results from the day before)
* News score
* Blood test for inflammatory markers (IL-6, IL-1β, IL-12, TNF α, IFN-γ) (local)
* D-Dimer test (local)
* VAS scale
* Test for detection COVID-19
* Urine pregnancy test for women of childbearing potential
* ECG
* COVID-19-Impact on Quality of Life Questionnaire (will be completed by the staff based on the patient answer)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1 - CimetrA-1
a total dose containing a combination of Artemisinin 12 mg, Curcumin 40 mg, Boswellia 30 mg, and Vitamin C 120 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
Confirm SARS-CoV-2 infection
patients will be tested for SARS-CoV-2 on days 1, 14 and 28
Physical Examination
patients will undergo a physical examination on days 1-14 and day 28
Vital Signs
patient's vital signs will be measured on days 1-14 and day 28
Hematology blood test
patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
Biochemistry blood test
patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
NEWS score
patient's NEWS score will be evaluated on days 1-14 and day 28
PK test
PK test will be performed on day 1 only (only in Brazil sites)
blood test for inflammatory markers
patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
D-dimer test
patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
VAS scale
patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
Urine pregnancy test for women of childbearing potential
patients will provide a urine sample for a urine pregnancy test on days 1, and day 28
ECG
patients will undergo an ECG examination on days 1, and day 28
COVID-19-Impact on Quality of Life Questionnaire
patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28
CimetrA-1
patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care
Arm 2 - CimetrA-2
a total dose containing a combination of Artemisinin 8.4 mg, Curcumin 28 mg, Boswellia 21 mg, and Vitamin C 84 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
Confirm SARS-CoV-2 infection
patients will be tested for SARS-CoV-2 on days 1, 14 and 28
Physical Examination
patients will undergo a physical examination on days 1-14 and day 28
Vital Signs
patient's vital signs will be measured on days 1-14 and day 28
Hematology blood test
patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
Biochemistry blood test
patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
NEWS score
patient's NEWS score will be evaluated on days 1-14 and day 28
PK test
PK test will be performed on day 1 only (only in Brazil sites)
blood test for inflammatory markers
patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
D-dimer test
patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
VAS scale
patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
Urine pregnancy test for women of childbearing potential
patients will provide a urine sample for a urine pregnancy test on days 1, and day 28
ECG
patients will undergo an ECG examination on days 1, and day 28
COVID-19-Impact on Quality of Life Questionnaire
patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28
CimetrA-2
patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
Arm 3 - Placebo
composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
Placebo administration
patients will receive the placebo treatment in addition to Standard of Care
Confirm SARS-CoV-2 infection
patients will be tested for SARS-CoV-2 on days 1, 14 and 28
Physical Examination
patients will undergo a physical examination on days 1-14 and day 28
Vital Signs
patient's vital signs will be measured on days 1-14 and day 28
Hematology blood test
patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
Biochemistry blood test
patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
NEWS score
patient's NEWS score will be evaluated on days 1-14 and day 28
PK test
PK test will be performed on day 1 only (only in Brazil sites)
blood test for inflammatory markers
patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
D-dimer test
patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
VAS scale
patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
Urine pregnancy test for women of childbearing potential
patients will provide a urine sample for a urine pregnancy test on days 1, and day 28
ECG
patients will undergo an ECG examination on days 1, and day 28
COVID-19-Impact on Quality of Life Questionnaire
patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo administration
patients will receive the placebo treatment in addition to Standard of Care
Confirm SARS-CoV-2 infection
patients will be tested for SARS-CoV-2 on days 1, 14 and 28
Physical Examination
patients will undergo a physical examination on days 1-14 and day 28
Vital Signs
patient's vital signs will be measured on days 1-14 and day 28
Hematology blood test
patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
Biochemistry blood test
patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
NEWS score
patient's NEWS score will be evaluated on days 1-14 and day 28
PK test
PK test will be performed on day 1 only (only in Brazil sites)
blood test for inflammatory markers
patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
D-dimer test
patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
VAS scale
patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
Urine pregnancy test for women of childbearing potential
patients will provide a urine sample for a urine pregnancy test on days 1, and day 28
ECG
patients will undergo an ECG examination on days 1, and day 28
COVID-19-Impact on Quality of Life Questionnaire
patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28
CimetrA-1
patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care
CimetrA-2
patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Hospitalized patient with COVID-19 of moderate stable or worsening severity not requiring ICU admission.
3. Age: 18 years old and above.
4. Subjects must be under observation or admitted to a controlled facility or hospital (home quarantine is not sufficient).
5. Ability to receive treatment by spray into the oral cavity
Exclusion Criteria
2. Patients with scores 5 or above per the Ordinal Scale for Clinical Improvement published by the WHO. (i.e., who need oxygen supply beyond use of nozzles or simple mask)
3. Need for admission to ICU during the present hospitalization at any time prior to completion of the recruitment to the study.
4. Any condition which, in the opinion of the Principal Investigator, would prevent full participation in this trial or would interfere with the evaluation of the trial endpoints.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MGC Pharmaceuticals d.o.o
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nazareth Hospital EMMS
Nazareth, North, Israel
Rambam Medical Center
Haifa, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MGC-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.